MRNA
NASDAQModerna Inc.
Price$47.41-3.40 (-6.69%)
01:30 PM07:45 PM
News · 26 weeks97-30%
2025-12-072026-05-31
Mix4490d
- Insider22(50%)
- Market13(30%)
- SEC Filings6(14%)
- Other3(7%)
Latest news
25 items- INSIDERChief Financial Officer Mock James M converted options into 2,475 shares and covered exercise/tax liability with 1,197 shares, increasing direct ownership by 2% to 59,594 units (SEC Form 4) to satisfy tax liability4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERChief Legal Officer Klinger Shannon Thyme converted options into 2,165 shares and covered exercise/tax liability with 1,047 shares, increasing direct ownership by 2% to 67,468 units (SEC Form 4) (tax withholding)4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERPresident Hoge Stephen converted options into 9,282 shares and covered exercise/tax liability with 4,488 shares, increasing direct ownership by 0.32% to 1,483,848 units (SEC Form 4) to satisfy tax liability4 - Moderna, Inc. (0001682852) (Issuer)
- NEWSModerna to Present at Upcoming Conference in June 2026CAMBRIDGE, MA / ACCESS Newswire / June 2, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conference:Goldman Sachs 47th Annual Global Healthcare Conference 2026, on Tuesday, June 9th at 3:20 p.m. ETA live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.About ModernaModerna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made
- NEWSModerna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual MeetingAt a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death compared to KEYTRUDA aloneIntismeran autogene in combination with KEYTRUDA demonstrated an encouraging trend toward overall survival in an exploratory analysis compared to KEYTRUDA alone (HR=0.471; [95% CI, 0.165-1.345]) CAMBRIDGE, MA AND RAHWAY, NJ / ACCESS Newswire / June 1, 2026 / Moderna, Inc. (NASDAQ:MRNA) and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced detailed results f
- NEWSModerna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo EbolavirusCoalition for Epidemic Preparedness Innovations funding builds on Moderna's prior filovirus research and supports preclinical development and Phase 1 clinical evaluation CAMBRIDGE, MA / ACCESS Newswire / June 1, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced an expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a potential vaccine against Bundibugyo ebolavirus (BDBV), a cause of Ebola virus disease for which there are currently no licensed vaccines indicated.Under the agreement, CEPI has committed up to US $50 million to support preclinical development and Phase 1 clinical testing of Moderna's investigational BDBV vaccine
- INSIDERChief Financial Officer Mock James M converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 0.98% to 58,316 units (SEC Form 4) to satisfy tax liability4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERChief Legal Officer Klinger Shannon Thyme converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 0.86% to 66,350 units (SEC Form 4) (for tax liability)4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERPresident Hoge Stephen converted options into 2,047 shares and covered exercise/tax liability with 990 shares, increasing direct ownership by 0.07% to 1,479,054 units (SEC Form 4) (tax liability)4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERDirector Afeyan Noubar exercised 9,263 shares at a strike of $19.15 and sold $433,879 worth of shares (9,263 units at $46.84) (SEC Form 4)4 - Moderna, Inc. (0001682852) (Issuer)
- SECSEC Form 144 filed by Moderna Inc.144 - Moderna, Inc. (0001682852) (Subject)
- INSIDERPresident Hoge Stephen exercised 53,336 shares at a strike of $19.15 and sold $2,581,462 worth of shares (53,336 units at $48.40) as part of a pre-agreed trading plan (SEC Form 4)4 - Moderna, Inc. (0001682852) (Issuer)
- PRBiologics Market Momentum Accelerates Across Healthcare, AI, And Global Medical TourismDENVER, May 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) - The biologics sector is rapidly emerging as one of the most closely watched growth stories in healthcare as breakthroughs in immunotherapy, regenerative medicine, cell engineering, and AI-assisted drug development continue reshaping investor sentiment. Unlike traditional pharmaceutical compounds, biologics leverage complex biological systems to target diseases with greater specificity, opening new opportunities in cancer, autoimmune disorders, rare diseases, and regenerative therapies. The investment narrative around biologics has expanded far beyond drug development alone. Today, the sector sits at the intersection of artific
- NEWSModerna Recognized by TIME as One of the World's Most Impactful CompaniesCAMBRIDGE, MA / ACCESS Newswire / May 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked no. 1 on TIME's 2026 list of the World's Most Impactful Companies. The recognition highlights the Company's work as a pioneer of mRNA technology and its focus on delivering meaningful benefits for patients and society."We are honored to be recognized by TIME as one of the world's most impactful companies," said Stéphane Bancel, Chief Executive Officer of Moderna. "This reflects the dedication of our team to our mission and advancing mRNA science for patients. We remain focused on developing innovative medicines to address significant unmet needs, expanding the reach of our platform acro
- PRCNS Drug Delivery Breakthroughs Unlock Significant Biotech Market OpportunitiesAUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer's disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile), are working within a broader in
- SECModerna Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders8-K - Moderna, Inc. (0001682852) (Filer)
- INSIDERSEC Form 4 filed by Director Rubenstein David M.4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERSEC Form 4 filed by Director Hussain Abbas4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERSEC Form 4 filed by Director Horning Sandra4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERSEC Form 4 filed by Director Nabel Elizabeth G4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERSEC Form 4 filed by Director Nader Francois4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERSEC Form 4 filed by Director Tallett Elizabeth E4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERSEC Form 4 filed by Director Afeyan Noubar4 - Moderna, Inc. (0001682852) (Issuer)
- SECSEC Form 144 filed by Moderna Inc.144 - Moderna, Inc. (0001682852) (Subject)
- NEWSModerna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to begin in 2026 CAMBRIDGE, MA / ACCESS Newswire / May 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced a publication in the New England Journal of Medicine of the positive Phase 3 study results evaluating mRNA-1010, its vaccine candidate for seasonal influenza. The peer-reviewed article summarizes the safety and efficacy data from Moderna's Phase 3 study (P304) evaluating the relative vaccine efficacy (rVE) of mRNA-1010 against influenza illness compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older.As previously reported, mRNA-1010
MRNA FAQ
7 questionsWhat does Moderna Inc. do?
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with...Where does MRNA stock trade?
Moderna Inc. (MRNA) is listed on NASDAQ.What sector and industry is MRNA in?
Moderna Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Moderna Inc. go public?
Moderna Inc. (MRNA) completed its IPO in 2018.What are analysts saying about MRNA?
Moderna Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Equal Weight with a $2500.00 price target on 2026-01-28. Recent price targets range from $2500.00 to $4500.00.What companies are similar to MRNA?
Notable peers in the same industry include AZN (AstraZeneca PLC), MRK (Merck & Company Inc.), PFE (Pfizer Inc.), GSK (GSK plc), BNTX (BioNTech SE). Compare MRNA side-by-side with any of them on Quantisnow.How can I track MRNA on Quantisnow?
Quantisnow aggregates Moderna Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MRNA to receive live email and push alerts on every new disclosure.